Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 270 across all filing types
Latest filing 2026-04-13 Management Reports
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion & Analysis” for the six months ended February 28, 2026, providing management’s detailed explanation of financial results, business trends, liquidity, capital resources, and related party transactions. It is a standalone MD&A rather than the full interim financial statements. Under the filing definitions, MD&A falls under Management Reports (Code: MDA).
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a bi‐weekly press release updating the market on the status of a Management Cease Trade Order (MCTO) due to late filing of annual and interim financial reports. It is not the actual annual or interim report, nor an earnings release, proxy material, or other specific category. It provides a regulatory update and does not fit any specialized filing type. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2026-04-13 English
News release - English.pdf
Management Reports Classification · 1% confidence The document is a Management’s Discussion & Analysis (MD&A) for the six months ended February 28, 2026, containing management’s detailed explanation of financial results, business trends, operations, liquidity, and risk factors. It is not merely an earnings highlight, presentation, or announcement of a report, but the substantive MD&A itself. This aligns precisely with the definition of a Management Reports filing (MDA).
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release updating on the status of a management cease trade order and delayed continuous disclosure filings (annual and interim financial statements) under Canadian securities rules (NP 12-203 and NI 51-102). It is not the actual financial report nor an AGM presentation, earnings release, management discussion, or any other specialized form. It is a regulatory announcement/fallback news release informing the market of compliance status. Therefore, it best fits the fallback category “Regulatory Filings” (RNS).
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a bi-weekly news release updating investors on the status of a management cease-trade order (MCTO) and delayed continuous disclosure filings (annual and interim financial statements). It is not an earnings release, formal annual or interim report, dividend notice, or other specific category. It is a regulatory announcement informing the market of disclosure defaults under National Instrument 51-102 and NP 12-203. This aligns with a general regulatory filing/news service announcement (RNS).
2026-04-13 English
News release - English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a formal announcement of quarterly financial results for Jewett-Cameron Trading Company Ltd. for the fiscal 2026 second quarter. It includes a management discussion, detailed financial highlights, and full unaudited consolidated financial statements (Balance Sheets, Statements of Operations, and Statements of Cash Flows). Because it contains comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q2 2026
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.